Compare APGE & BCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APGE | BCPC |
|---|---|---|
| Founded | 2022 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.6B |
| IPO Year | 2023 | 1995 |
| Metric | APGE | BCPC |
|---|---|---|
| Price | $132.71 | $168.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 2 |
| Target Price | $109.67 | ★ $176.00 |
| AVG Volume (30 Days) | ★ 4.0M | 202.3K |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.55% |
| EPS Growth | N/A | ★ 20.87 |
| EPS | N/A | ★ 1.25 |
| Revenue | N/A | ★ $799,023,000.00 |
| Revenue This Year | N/A | $8.47 |
| Revenue Next Year | N/A | $4.89 |
| P/E Ratio | ★ N/A | $132.83 |
| Revenue Growth | N/A | ★ 13.56 |
| 52 Week Low | $34.34 | $139.17 |
| 52 Week High | $133.16 | $183.90 |
| Indicator | APGE | BCPC |
|---|---|---|
| Relative Strength Index (RSI) | 81.42 | 65.60 |
| Support Level | $75.41 | $167.19 |
| Resistance Level | N/A | $171.50 |
| Average True Range (ATR) | 4.21 | 3.07 |
| MACD | 5.57 | 0.97 |
| Stochastic Oscillator | 99.15 | 87.20 |
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.